| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology Group (Y.B., V.G.), McGill University Health Center, and Departments of Biochemistry, Medicine and Oncology (V.G.), Faculty of Medicine, McGill University, Montréal, Québec, Canada H3A 1A1
Address all correspondence and requests for reprints to: Vincent Giguère, Molecular Oncology Group, McGill University Health Centre, Room H5-21, 687 Pine Avenue West, Montréal, Québec, Canada H3A 1A1. E-mail: vincent.giguere{at}mcgill.ca.
Estrogen receptor (ER)
and -ß interact with a variety of coactivator proteins, most notably members of the steroid receptor coactivator (SRC) family, and these interactions have been shown to be regulated by estrogenic ligands and growth factor signaling. Here, using fluorescence resonance energy transfer (FRET), the selectivity of different stimulants on ER
and -ß interactions with coactivator receptor interaction domains (RIDs) were examined in living cells. We first show that ER
and ERß homo- and heterodimers form in vivo independently of the presence of 17ß-estradiol (E2) or antiestrogens. We then demonstrate that E2 enhances interactions between ER
and the RIDs of SRC-1 and SRC-3, whereas the interaction between ER
with the SRC-2 RID is ligand independent. The transcriptionally inactive mutant ER
L539A showed no interaction with all three SRC RIDs. Similarly, treatment with the antagonists 4-hydroxytamoxifen and EM-652 abolished all interactions between ER
and the SRC RIDs. FRET data also demonstrate that, in contrast to ER
, ERß interacts with all three SRC RIDs in a ligand-independent manner. However, these interactions were further enhanced or stabilized by E2, whereas the antiestrogen EM-652 abolished all interactions. In the presence of both ER
and ERß, E2 treatment led to the recruitment of SRC RIDs to the nuclei. Finally, expression of the oncogenic activated ErbB-2/Neu protein specifically enhanced ER
but not ERß interactions with SRC RIDs to an extent similar to E2-stimulated interactions. In summary, using FRET, we demonstrated preferential interactions between ER isoforms and coactivators upon hormonal treatment and activation of a growth factor signal transduction pathway in living cells.
NURSA Molecule Pages Link:
This article has been cited by other articles:
![]() |
S. L. Nott, Y. Huang, X. Li, B. R. Fluharty, X. Qiu, W. V. Welshons, S. Yeh, and M. Muyan Genomic Responses from the Estrogen-responsive Element-dependent Signaling Pathway Mediated by Estrogen Receptor {alpha} Are Required to Elicit Cellular Alterations J. Biol. Chem., May 29, 2009; 284(22): 15277 - 15288. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bourdeau, J. Deschenes, D. Laperriere, M. Aid, J. H. White, and S. Mader Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells Nucleic Acids Res., January 17, 2008; 36(1): 76 - 93. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-W. Jeong, K. Y. Lee, S. J. Han, B. J. Aronow, J. P. Lydon, B. W. O'Malley, and F. J. DeMayo The p160 Steroid Receptor Coactivator 2, SRC-2, Regulates Murine Endometrial Function and Regulates Progesterone-Independent and -Dependent Gene Expression Endocrinology, September 1, 2007; 148(9): 4238 - 4250. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Padron, L. Li, E. M. Kofoed, and F. Schaufele Ligand-Selective Interdomain Conformations of Estrogen Receptor-{alpha} Mol. Endocrinol., January 1, 2007; 21(1): 49 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mc Ilroy, F. J Fleming, Y. Buggy, A. D K Hill, and L. S Young Tamoxifen-induced ER-{alpha}-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence Endocr. Relat. Cancer, December 1, 2006; 13(4): 1135 - 1145. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Paulmurugan and S. S. Gambhir An intramolecular folding sensor for imaging estrogen receptor-ligand interactions PNAS, October 24, 2006; 103(43): 15883 - 15888. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Khan, R. Barhoumi, R. Burghardt, S. Liu, K. Kim, and S. Safe Molecular Mechanism of Inhibitory Aryl Hydrocarbon Receptor--Estrogen Receptor/Sp1 Cross Talk in Breast Cancer Cells Mol. Endocrinol., September 1, 2006; 20(9): 2199 - 2214. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C Murphy and P. H Watson Is oestrogen receptor- {beta} a predictor of endocrine therapy responsiveness in human breast cancer? Endocr. Relat. Cancer, June 1, 2006; 13(2): 327 - 334. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Copik, M. S. Webb, A. L. Miller, Y. Wang, R. Kumar, and E. B. Thompson Activation Function 1 of Glucocorticoid Receptor Binds TATA-Binding Protein in Vitro and in Vivo Mol. Endocrinol., June 1, 2006; 20(6): 1218 - 1230. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Abdelrahim, E. Ariazi, K. Kim, S. Khan, R. Barhoumi, R. Burghardt, S. Liu, D. Hill, R. Finnell, B. Wlodarczyk, et al. 3-Methylcholanthrene and Other Aryl Hydrocarbon Receptor Agonists Directly Activate Estrogen Receptor {alpha} Cancer Res., February 15, 2006; 66(4): 2459 - 2467. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Huang, X. Li, C. A. Maguire, R. Hilf, R. A. Bambara, and M. Muyan Binding of Estrogen Receptor {beta} to Estrogen Response Element in Situ Is Independent of Estradiol and Impaired by Its Amino Terminus Mol. Endocrinol., November 1, 2005; 19(11): 2696 - 2712. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. N. Day and F. Schaufele Imaging Molecular Interactions in Living Cells Mol. Endocrinol., July 1, 2005; 19(7): 1675 - 1686. [Abstract] [Full Text] [PDF] |
||||
![]() |
E E Connor, D L Wood, T S Sonstegard, A F da Mota, G L Bennett, J L Williams, and A V Capuco Chromosomal mapping and quantitative analysis of estrogen-related receptor alpha-1, estrogen receptors alpha and beta and progesterone receptor in the bovine mammary gland J. Endocrinol., June 1, 2005; 185(3): 593 - 603. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Feige, L. Gelman, C. Tudor, Y. Engelborghs, W. Wahli, and B. Desvergne Fluorescence Imaging Reveals the Nuclear Behavior of Peroxisome Proliferator-activated Receptor/Retinoid X Receptor Heterodimers in the Absence and Presence of Ligand J. Biol. Chem., May 6, 2005; 280(18): 17880 - 17890. [Abstract] [Full Text] [PDF] |
||||
![]() |
L C Murphy, B Peng, A Lewis, J R Davie, E Leygue, A Kemp, K Ung, M Vendetti, and R Shiu Inducible upregulation of oestrogen receptor-{beta}1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells J. Mol. Endocrinol., April 1, 2005; 34(2): 553 - 566. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kim, R. Barhoumi, R. Burghardt, and S. Safe Analysis of Estrogen Receptor {alpha}-Sp1 Interactions in Breast Cancer Cells by Fluorescence Resonance Energy Transfer Mol. Endocrinol., April 1, 2005; 19(4): 843 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Wu, R. Burghardt, and S. Safe Vitamin D-interacting Protein 205 (DRIP205) Coactivation of Estrogen Receptor {alpha} (ER{alpha}) Involves Multiple Domains of Both Proteins J. Biol. Chem., December 17, 2004; 279(51): 53602 - 53612. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Geraldes, M. G. Sirois, and J.-F. Tanguay Specific Contribution of Estrogen Receptors on Mitogen-Activated Protein Kinase Pathways and Vascular Cell Activation Circ. Res., September 5, 2003; 93(5): 399 - 405. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |